Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy
Authors:
Open Access
- 30 March 2022
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 10 (3) , e004421
Abstract
Background In patients receiving immune checkpoint inhibitor (ICI) therapy, acute kidney injury (AKI) is common, and can occur either from kidney injury unrelated to ICI use or from immune activation resulting in acute interstitial nephritis (AIN). In this study, we test the hypothesis that occurrence of AIN indicates a favorable treatment response to ICI therapy and therefore among patients who develop AKI while on ICI therapy, those with AIN will demonstrate greater survival compared with others with AKI. Methods In this observational cohort study, we included participants initiated on ICI therapy between 2013 and 2019. We tested the independent association of AKI and estimated AIN (eAIN) with mortality up to 1 year after therapy initiation as compared with those without AKI using time-varying Cox proportional hazard models controlling for demographics, comorbidities, cancer type, stage, and therapy, and baseline laboratory values. We defined eAIN as those with a predicted probability of AIN >90th percentile derived from a recently validated diagnostic model. Results Of 2207 patients initiated on ICIs, 617 (28%) died at 1 year and 549 (25%) developed AKI. AKI was independently associated with higher mortality (adjusted HR, 2.28 (95% CI 1.90 to 2.72)). Those AKI patients with eAIN had more severe AKI as reflected by a higher peak serum creatinine (3.3 (IQR 2.1–6.1) vs 1.4 (1.2–1.9) mg/dL, pConclusion In patients treated with ICI, mortality was higher in those with AKI unrelated to ICI but lower in those where the underlying etiology was AIN. Future studies could evaluate the association of biopsy-proven or biomarker-proven AIN with mortality in those receiving ICI therapy.Keywords
Funding Information
- National Institutes of Health (K23DK117065, R01DK128087)
This publication has 50 references indexed in Scilit:
- Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitorsKidney International, 2016
- Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with OutcomesClinical Cancer Research, 2016
- Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With PembrolizumabJAMA Dermatology, 2016
- Drug-induced Acute Interstitial Nephritis Pathology, Pathogenesis, and Treatment2015
- Diagnosing drug-induced AIN in the hospitalized patient: A challenge for the clinicianClinical Nephrology, 2014
- Percutaneous Renal Biopsy of Native Kidneys: A Single-Center Experience of 1,055 BiopsiesAmerican Journal of Nephrology, 2014
- Estimating Baseline Kidney Function in Hospitalized Patients with Impaired Kidney FunctionClinical Journal of the American Society of Nephrology, 2012
- KDIGO Board MembersKidney International Supplements, 2012
- NoticeKidney International Supplements, 2012
- Renal Biopsy Findings in Acute Renal Failure in the Cohort of Patients in the Spanish Registry of GlomerulonephritisClinical Journal of the American Society of Nephrology, 2008